Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
Metabolic dysfunction-Associated Steatotic Liver Disease
Fatty Liver Disease (NAFLD and NASH)
Follow us on LinkedIn - https://www.linkedin.com/company/fatty-liver-alliance/
Fatty Liver Disease (NAFLD and NASH)
Incredible days ahead at the joint CDDW-CLM Conference in Toronto. Fatty Liver Alliance with Canadian Association for the Study of the Liver and CanNASH are hosting a FibroScan Lounge for attendees so that they can have their liver health assessed.
Early liver disease detection is very important and we thank Liver Scan Direct and Sentrex Health Solutions for sponsoring this initiative.
"From Gut Feelings to Gut Healings: Navigating the Bacterial Jungle Inside Us for Better Liver Health". What is microbiota and how does it impact your liver health, and specifically MASLD and MASH? Silvia Sookoian. M.D. Ph.D. and Michael Betel discuss this important and less often discussed topic. Interest in this area is exploding and today's blog is a great overview.
In March 2023, the Fatty Liver Alliance, along with the Canadian Association for the Study of the Liver (CASL) and the Canadian NASH Network (CanNASH), embarked on a mission to highlight the significance of early and non-invasive, liver health assessments, by hosting a dedicated location for private liver health assessments, known as the ‘Fibroscan® Lounge’, at the Joint CDDW-CLM Liver Meeting, held in Toronto.
At the conference, 104 attendees volunteered for a liver health assessment and both the Steatosis (CAP Score) and Fibrosis (kPa Score) were measured.
What were the results? Check out our blog to find out!
The response to Professor Mazen Noureddin, MD, MHSc's presentation at the American Association for the Study of Liver Diseases (AASLD) Precision Medicine Conference this past weekend was so overwhelmingly positive, that we wrote a blog and shared more of the 'bigger picture' from his presentation (with a few journal references).
In today’s blog, we summarize the key takeaways:
1. Precision Medicine's Role in MASH
2. Importance of Addressing Fibrosis
3. Combination Therapies Potential
4. Treatment Approaches
Dr. Stephen Harrison eloquently states, "Exercise is critically important, but here's a little caveat about exercise. You cannot out-exercise the fork." (1) This simple yet profound statement encapsulates a fundamental truth about health and wellness: the food we eat plays a crucial role in our health outcomes, often more so than the amount of exercise we engage in.
The transition from the term Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and its severe form, Metabolic Dysfunction-Associated Steatohepatitis (MASH), reflects a significant shift in understanding and characterizing this liver condition. This change aims to better capture the disease's association with metabolic dysfunction and to move away from a definition that primarily excludes alcohol consumption as a cause.
Global estimates of fatty liver disease (MASLD) exceed 38%, and this epidemic needs to be addressed with urgency. Jeffrey V. Lazarus et al., in this article (published in Hepatology), discuss an action plan to address this global epidemic. It won't be easy, but we need to work together and we need to start now.
Our amazing team of full and part-time volunteers are committed to helping others. We take our convictions and turn them into action. Think you would be a good fit? Get in touch for more information!
Our nonprofit charity was created to build a supportive community. Canada’s population is about 38.8M with an estimated 11.64M who may have Metabolic Dysfunction Associated Liver Disease (MASLD) (formerly NAFLD). Of those, an estimated 20% - 25% will progress to cirrhosis and suffer with Metabolic-dysfunction Associated Steatohepatitis (MASH) (formerly NASH).
We raise awareness about the risks, causes and complications of fatty liver disease and help those already diagnosed with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) by advocating for access to approved treatments and care.
Your support and contributions will enable our Registered Charity to meet our goals and your generous donations will fund our mission and purpose. Charity #79690 4704 RR0001
We will issue a tax receipt for donations of $18.00 or greater.
**Best option for us, is e-transfer to donations@fattyliver.ca
In the comment section, we need your full name and address so we can issue a tax receipt. Other payment options below.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.